Loading
A phase 3 trial of Olaparib in ovarian cancer, run by AstraZeneca, active and no longer recruiting.
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib is a phase 3 interventional study registered as NCT04421963 by AstraZeneca, with 185 participants enrolled, started 2020-08-04 and due to reach its primary completion in 2027-04-06. Interventions recorded: Olaparib. Conditions listed: Ovarian Cancer, Breast Cancer. No results are recorded here; the registry entry is the source.
Shares PARP inhibitors, Olaparib, AstraZeneca, Ovarian cancer.
Shares PARP inhibitors, Olaparib, AstraZeneca, Ovarian cancer.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares PARP inhibitors, Olaparib, AstraZeneca, Ovarian cancer.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares PARP inhibitors, Olaparib, Ovarian cancer.